@article{81d2f1a824da4aa3919bf22a4921b619,
title = "Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial",
abstract = "We report interim 24-weeks efficacy data of ATLAS-M trial, a phase IV, multicentre, open-label, randomized study designed to show 48-weeks, non-inferior efficacy (margin of -12%) of treatment simplification to atazanavir/ritonavir (ATV/r)+lamivudine (3TC) versus maintaining 3-drugs ATV/r-based cART.",
keywords = "HIV, simplification, HIV, simplification",
author = "Massimiliano Fabbiani and {Di Giambenedetto}, Simona and {Quiros Roldan}, E and A Latini and V Vullo and A Antinori and A Castagna and G Orofino and D Francisci and E Grilli and G Madeddu and Pierfrancesco Grima and S Rusconi and {Del Pin}, B and Annalisa Mondi and Alberto Borghetti and E Foc{\`a} and Manuela Colafigli and {De Luca}, Andrea and Roberto Cauda",
year = "2014",
language = "English",
volume = "17",
pages = "19808--19808",
journal = "Journal of the International AIDS Society",
issn = "1758-2652",
publisher = "London: BioMed Central",
note = "HIV Drug Therapy Glasgow Congress 2014 ; Conference date: 02-11-2014 Through 06-11-2014",
}